Kolon Life Science Balance Sheet Health
Financial Health criteria checks 1/6
Kolon Life Science has a total shareholder equity of ₩127.8B and total debt of ₩124.4B, which brings its debt-to-equity ratio to 97.4%. Its total assets and total liabilities are ₩356.4B and ₩228.6B respectively.
Key information
97.4%
Debt to equity ratio
₩124.39b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩25.56b |
| Equity | ₩127.77b |
| Total liabilities | ₩228.58b |
| Total assets | ₩356.36b |
Recent financial health updates
We Think Kolon Life Science (KOSDAQ:102940) Has A Fair Chunk Of Debt
Mar 12
Kolon Life Science (KOSDAQ:102940) Is Carrying A Fair Bit Of Debt
Nov 26
Recent updates
Risks Still Elevated At These Prices As Kolon Life Science Inc. (KOSDAQ:102940) Shares Dive 26%
Mar 02We Think Kolon Life Science (KOSDAQ:102940) Has A Fair Chunk Of Debt
Mar 12A Look At Kolon Life Science's (KOSDAQ:102940) Share Price Returns
Jan 18Kolon Life Science (KOSDAQ:102940) Is Carrying A Fair Bit Of Debt
Nov 26Financial Position Analysis
Short Term Liabilities: A102940's short term assets (₩114.2B) do not cover its short term liabilities (₩183.0B).
Long Term Liabilities: A102940's short term assets (₩114.2B) exceed its long term liabilities (₩45.5B).
Debt to Equity History and Analysis
Debt Level: A102940's net debt to equity ratio (77.3%) is considered high.
Reducing Debt: Insufficient data to determine if A102940's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A102940 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: A102940 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 1.2% each year